Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Pipeline Review, H2 2018
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Pipeline Review, H2 2018
SUMMARY
According to the recently published report 'Superoxide Dismutase [Cu-Zn] - Pipeline Review, H2 2018'; Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) pipeline Target constitutes close to 16 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of the superoxide (O2?) radical into either ordinary molecular oxygen (O2) or hydrogen peroxide (H2O2) which prevents damage to tissues. Superoxide dismutase is used for treating pain and swelling (inflammation) caused by osteoarthritis, sports injuries, and rheumatoid arthritis, a kidney condition called interstitial cystitis, gout, poisoning caused by a weed-killer called paraquat, cancer, and lung problems in newborns.
The report 'Superoxide Dismutase [Cu-Zn] - Pipeline Review, H2 2018' outlays comprehensive information on the Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 8 and 1 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Genetic Disorders which include indications Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Parkinson's Disease and Wilson Disease.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Superoxide Dismutase [Cu-Zn] - Pipeline Review, H2 2018'; Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) pipeline Target constitutes close to 16 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of the superoxide (O2?) radical into either ordinary molecular oxygen (O2) or hydrogen peroxide (H2O2) which prevents damage to tissues. Superoxide dismutase is used for treating pain and swelling (inflammation) caused by osteoarthritis, sports injuries, and rheumatoid arthritis, a kidney condition called interstitial cystitis, gout, poisoning caused by a weed-killer called paraquat, cancer, and lung problems in newborns.
The report 'Superoxide Dismutase [Cu-Zn] - Pipeline Review, H2 2018' outlays comprehensive information on the Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 8 and 1 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Genetic Disorders which include indications Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Parkinson's Disease and Wilson Disease.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)
- The report reviews Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Overview
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Companies Involved in Therapeutics Development
AL-S Pharma AG
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
AveXis Inc
Ionis Pharmaceuticals Inc
Priavoid GmbH
ProMIS Neurosciences Inc
Voyager Therapeutics Inc
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Drug Profiles
Antisense RNAi Oligonucleotides to Inhibit Superoxide Dismutase for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVXS-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit SOD1 for Amyotropic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMN-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMN-120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMN-130 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RNAi Gene Therapy to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate SOD-1 for Amyotrophic Lateral Sclerosis and Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Superoxide Dismutase 1 for Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TDI-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THN-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tofersen sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VYSOD-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WTX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Dormant Products
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Product Development Milestones
Featured News & Press Releases
Jul 25, 2018: Next-generation ALS drug silences inherited form of the disease in animal models
Jul 16, 2018: Washington University’s new ALS therapy in clinical trial stage
Jun 01, 2018: Wilson Therapeutics to present data from WTX101 Phase 2 extension study at 4th Congress of the European Academy of Neurology
May 17, 2018: Voyager Therapeutics Announces New Data on VY-SOD101 at the American Society of Gene and Cell Therapy 2018 Annual Meeting
Apr 12, 2018: Promising preliminary long-term data for WTX101 in Wilson Disease presented at EASL Annual Meeting
Mar 28, 2018: Preliminary Long-Term Data For WTX101 In Wilson Disease Accepted As A Late-Breaker Presentation At EASL Annual Meeting
Feb 16, 2018: First patient enrolled in pivotal Phase 3 FOCuS trial evaluating WTX101 for the treatment of Wilson Disease
Dec 14, 2017: WTX101 Granted Fast Track Designation by the U.S. FDA for the Treatment of Wilson Disease
Oct 23, 2017: Wilson Therapeutics reaches agreement with the FDA and EMA to initiate pivotal Phase 3 FOCuS study with WTX101 in Wilson Disease
Oct 20, 2017: Promising Preliminary Long-term Data For WTX101 In Wilson Disease Highlighted at The Liver Meeting
Oct 06, 2017: Phase 2 Clinical Trial Data for WTX101 Published in The Lancet Gastroenterology & Hepatology
Oct 01, 2017: Promising Preliminary Long-term Data from WTX101 Phase 2 Extension Study to be Presented at AASLD Annual Meeting
Jun 09, 2017: Wilson Therapeutics Receives US Orphan Drug Designation for WTX101 for the Treatment of ALS
Jun 08, 2017: Wilson Therapeutics presents Phase 2 data for WTX101 at MDS meeting
Apr 25, 2017: Wilson Therapeutics presents promising neurological Phase 2 data for WTX101 at AAN meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Overview
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Companies Involved in Therapeutics Development
AL-S Pharma AG
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
AveXis Inc
Ionis Pharmaceuticals Inc
Priavoid GmbH
ProMIS Neurosciences Inc
Voyager Therapeutics Inc
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Drug Profiles
Antisense RNAi Oligonucleotides to Inhibit Superoxide Dismutase for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVXS-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit SOD1 for Amyotropic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMN-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMN-120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMN-130 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RNAi Gene Therapy to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate SOD-1 for Amyotrophic Lateral Sclerosis and Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Superoxide Dismutase 1 for Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TDI-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THN-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tofersen sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VYSOD-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WTX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Dormant Products
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Product Development Milestones
Featured News & Press Releases
Jul 25, 2018: Next-generation ALS drug silences inherited form of the disease in animal models
Jul 16, 2018: Washington University’s new ALS therapy in clinical trial stage
Jun 01, 2018: Wilson Therapeutics to present data from WTX101 Phase 2 extension study at 4th Congress of the European Academy of Neurology
May 17, 2018: Voyager Therapeutics Announces New Data on VY-SOD101 at the American Society of Gene and Cell Therapy 2018 Annual Meeting
Apr 12, 2018: Promising preliminary long-term data for WTX101 in Wilson Disease presented at EASL Annual Meeting
Mar 28, 2018: Preliminary Long-Term Data For WTX101 In Wilson Disease Accepted As A Late-Breaker Presentation At EASL Annual Meeting
Feb 16, 2018: First patient enrolled in pivotal Phase 3 FOCuS trial evaluating WTX101 for the treatment of Wilson Disease
Dec 14, 2017: WTX101 Granted Fast Track Designation by the U.S. FDA for the Treatment of Wilson Disease
Oct 23, 2017: Wilson Therapeutics reaches agreement with the FDA and EMA to initiate pivotal Phase 3 FOCuS study with WTX101 in Wilson Disease
Oct 20, 2017: Promising Preliminary Long-term Data For WTX101 In Wilson Disease Highlighted at The Liver Meeting
Oct 06, 2017: Phase 2 Clinical Trial Data for WTX101 Published in The Lancet Gastroenterology & Hepatology
Oct 01, 2017: Promising Preliminary Long-term Data from WTX101 Phase 2 Extension Study to be Presented at AASLD Annual Meeting
Jun 09, 2017: Wilson Therapeutics Receives US Orphan Drug Designation for WTX101 for the Treatment of ALS
Jun 08, 2017: Wilson Therapeutics presents Phase 2 data for WTX101 at MDS meeting
Apr 25, 2017: Wilson Therapeutics presents promising neurological Phase 2 data for WTX101 at AAN meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AL-S Pharma AG, H2 2018
Pipeline by Alexion Pharmaceuticals Inc, H2 2018
Pipeline by Alnylam Pharmaceuticals Inc, H2 2018
Pipeline by AveXis Inc, H2 2018
Pipeline by Ionis Pharmaceuticals Inc, H2 2018
Pipeline by Priavoid GmbH, H2 2018
Pipeline by ProMIS Neurosciences Inc, H2 2018
Pipeline by Voyager Therapeutics Inc, H2 2018
Dormant Projects, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AL-S Pharma AG, H2 2018
Pipeline by Alexion Pharmaceuticals Inc, H2 2018
Pipeline by Alnylam Pharmaceuticals Inc, H2 2018
Pipeline by AveXis Inc, H2 2018
Pipeline by Ionis Pharmaceuticals Inc, H2 2018
Pipeline by Priavoid GmbH, H2 2018
Pipeline by ProMIS Neurosciences Inc, H2 2018
Pipeline by Voyager Therapeutics Inc, H2 2018
Dormant Projects, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
AL-S Pharma AG
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
AveXis Inc
Ionis Pharmaceuticals Inc
Priavoid GmbH
ProMIS Neurosciences Inc
Voyager Therapeutics Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
AL-S Pharma AG
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
AveXis Inc
Ionis Pharmaceuticals Inc
Priavoid GmbH
ProMIS Neurosciences Inc
Voyager Therapeutics Inc
